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Abstract: Hypoglycaemia, hyperglycaemia and blood glucose (BG) variability are associated with 
worsened outcomes in critical care. However, NICE-SUGAR trial showed no clinical benefit from intensive 
insulin therapy. This study compares the table-based NICE-SUGAR and model-based STAR protocols to 
assess their relative capability to achieve safe, effective control for all patients. Validated virtual patients 
(n=443) were used to simulate glycaemic outcomes of the NICE-SUGAR and STAR protocols. Key 
outcomes evaluate tightness and safety of control for all patients: %BG in 80–144 mg/dL range (PTR); Per-
Patient Mean BG (PPM_BG); and Incidence of Hypoglycaemia (BG<40 mg/dL). These metrics determine 
performance overall, for each patient, and safety. Results are assessed for NICE-SUGAR measuring per-
protocol (~24/day) and at reported average rate (~3-hourly; ~8/day). STAR measures 1-3-hourly, averaging 
12/day. 
Per-protocol, STAR provided tight control, with higher PTR (90.7% vs. 78.3%) and tighter median [IQR] 
PPM_BG (112[106-119] vs. 117[106–137] mg/dL), and greater safety from hypoglycaemia (5 (1%) vs. 10 
patients (2.5%)) compared to NICE-SUGAR simulations as per protocol. The 5-95th percentile range 
PPM_BG for NICE-SUGAR (97–185 mg/dL) showed ~5% of NICE-SUGAR patients had mean BG above 
180mg/dL matching clinically reported performance. STAR’s 5th-90th PPM_BG percentile range was (97–
146 mg/dL). Measuring as recorded clinically, NICE-SUGAR had PTR of 77%, PPM_BG of 122 [110-
140] mg/dL and 24(6%) of patients experienced hypoglycaemia. These results match clinically reported 
values well (mean BG 115 vs. 118 mg/dL clinically vs. simulation, clinically 7% of patients had a 
hypoglycaemic event). 
Glycaemic control protocols need to be both safe and effective for all patients before potential clinical 
benefits can be assessed. NICE-SUGAR clinical results do not match results expected from their protocol, 
and show reduced safety and performance in comparison to STAR. 
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1. INTRODUCTION 
Hypoglycaemia, hyperglycaemia, and blood glucose (BG) 
variability are associated with higher mortality and worsened 
outcomes in critical care units (ICU), including severe 
infection, sepsis and septic shock, myocardial infarction, and 
multiple organ failure (McCowen et al., 2001, Capes et al., 
2000, Krinsley, 2003, Krinsley, 2009, Bagshaw et al., 2009, 
Van den Berghe et al., 2006a). Early studies showed benefits 
from intensive insulin therapy in the ICU (Van den Berghe et 
al., 2001, Van den Berghe et al., 2003, Krinsley, 2004, Chase 
et al., 2008b), with improved outcomes (Chase et al., 2010a, 
Van den Berghe et al., 2003), reduced mortality, and reduction 
of patient length of stay and nurse workload (Krinsley, 2005, 
Van den Berghe et al., 2006b). However, more recent trials 
have failed to reproduce these results, and have shown higher 
risks of hypoglycaemia (Griesdale et al., 2009, Wiener et al., 
2008, Preiser et al., 2009, Finfer et al., 2009). 
NICE-SUGAR is the largest multicentre and multinational 
randomised clinical trial to date, assessing intensive versus 
conventional glycaemic control in critically ill patients. This 
study showed no clinical benefit from intensive insulin 
therapy, with higher risks of hypoglycaemia and increased 
mortality in this group (Finfer et al., 2009, Finfer et al., 
2012). As a result, there is much debate surrounding the 
benefits of insulin therapy, and its application in ICU (Marik, 
2016, Preiser and Straaten, 2016). 
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One explanation for these conflicting results is the role of 
increased hypoglycaemia and BG variability in confounding 
results (Bagshaw et al., 2009, Egi et al., 2010, Penning et al., 
2014, Krinsley and Preiser, 2015). In order to adequately test 
the improved outcome hypothesis, insulin therapy must be 
carried out in a safe and effective manner, and be consistently 
achieved for all or nearly all patients (Chase et al., 2010a). In 
addition, glycaemic control protocols must effectively manage 
metabolic variability, which drives glycaemic outcome (Chase 
et al., 2011). Thus, fixed table-based or ad hoc protocols, often 
used in hospital ICUs, lack patient specificity and rely on 
clinical judgement, often failing to account for such 
variability. 
STAR (Stochastic TARgeted) is a clinically validated model-
based glycaemic control framework (Evans et al., 2012, Fisk 
et al., 2012, Stewart et al., 2016). It uses model-based insulin 
sensitivity to characterise and forward predict changes in 
metabolic state. Insulin and nutrition treatments are selected 
such that forward predictions of likely BG outcomes are within 
the target range, and the treatment does not exceed a 5% 
likelihood of BG ≤ 4.0 mmol/L. STAR as shown promising 
results in the adult ICU, and is in current use in ICUs in the 
Christchurch, New Zealand, and Gyula, Hungary. 
This paper compares the paper-based NICE-SUGAR protocol 
and the model-based STAR framework to assess their relative 
capability to achieve safe, effective control for all patients 
using a clinically validated virtual patient and virtual trials 
simulation system (Chase et al., 2010b). In doing so, it also 
evaluates how NICE-SUGAR performed clinically compared 
to a perfectly compliant virtual trial and its impact on 
performance and safety. 
2. METHODS 
2.1 Virtual Patients 
This analysis uses 443 virtual patients (Chase et al., 2010b) 
generated from a cohort using the SPRINT (Specialised 
Relative Insulin Nutrition Table) glycaemic protocol in 
Christchurch Hospital ICU, New Zealand, between 2005 and 
2007. In these 443 patients, gaps were removed and only 
patients that had an initial BG > 7 mmol/L (125 mg/dL) were 
included (Stewart et al., 2016). 
2.2 NICE-SUGAR and STAR protocols  
The NICE-SUGAR study was a randomised control trial with 
two arms: intensive insulin therapy and conventional control. 
The paper-based protocol for both groups is available online 
(Australia and New Zealand Intensive Care Society Clinical 
Trials Group et al., 2008) and are simulated here using 
clinically validated virtual trials (Chase et al., 2010b). This 
approach allows a large number of patients to be tested under 
multiple protocols for direct comparison. 
The NICE-SUGAR intensive insulin therapy protocol (NS-
IIT) targeted a glycaemic range of 4.5-6.0 mmol/l (81-108 
mg/dL), where the conventional control was < 10.0 mmol/L (< 
180mg/dL). For both aims, insulin was delivered as a 
continuous intravenous infusion of insulin alongside glucose 
boluses, and the nutritional management was carried out at the 
discretion of the treating clinicians (Finfer et al., 2009). 
Further explanation of this risk-based approach protocol can 
be found in (Finfer et al., 2009). NS-IIT was implemented 
directly from the reported protocol, and nutrition increased in 
simulation daily to reflect reported non-protein calorie 
achievements (Finfer et al., 2009). As nutrition 
type/composition was never reported, and ICU nutrition types 
can vary in their glucose composition, it was assumed that 
enteral nutrition was low carb (~40% of non-protein calories 
were CHO, similar to Glucerna 1.0TM), and that parenteral 
nutrition had 70% of non-protein calories attributable to CHO. 
Simulating with a low-carb enteral nutrition is conservative, 
and reflects a best case outcome for the NICE-SUGAR 
protocol, as increased dextrose intake tends to make glycaemic 
control more difficult and magnifies patient variability. 
STAR differs from NICE-SUGAR as it is a computerised 
model-based glycaemic control protocol, and uses a stochastic 
model to assess likely future change of patient-specific time-
varying insulin sensitivity (SI) (Evans et al., 2012, Lin et al., 
2008, Fisk et al., 2012). Current SI is determined from the 
clinically validated ICING physiological model (Lin et al., 
2011), using integral-based fitting methods (Hann et al., 2005).  
A stochastic model was built based on population data, 
allowing forecasting of future changes in SI, and thus BG for 
a given insulin/nutrition combinations, and thus corresponding 
BG outcomes. STAR selects an optimal insulin and nutrition 
dose to best overlap predicted BG outcomes with the BG target 
range (4.4-8.0 mmol/L or 80-144 mg/dL), maximizing both 
safety and performance. Hypoglycaemic risk is directly 
managed, with the predicted likelihood of BG < 4.4 mmol/L 
(< 80 mg/dL) limited to a maximum value of 5%, by directly 
placing the BG outcome for the 95th percentile future SI value 
on 4.4 mmol/L.  
Insulin is administered as boluses and enteral nutrition is 
modulated between 30-100% goal feed (Fisk et al., 2012), 
although actual delivery averaged ~90% of goal feed of 
~2000kcal/day for the average individual (Stewart et al., 
2016).  
2.3 Analyses of performance and safety  
Simulated glycaemic control outcomes for STAR and NS-IIT 
are compared. Performance is assessed by the percentage time 
of hourly resampled BG measurements in 4.4-8.0 mmol/L (80-
144mg/dL) band, and per-patient mean BG, similar to the 
reporting in the NICE-SUGAR study (Finfer et al., 2009). 
Safety is evaluated as the number of severe hypoglycaemic 
events, defined as BG level < 2.2 mmol/L (40mg/dL) and the 
overall %BG < 4.0 mmol/L (< 72 mg/dL), where the first 
safety outcome was also reported in the NICE-SUGAR study. 
While the original NICE-SUGAR papers (Finfer et al., 2009, 
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Finfer et al., 2012) report very little BG stats and glycaemic 
control outcomes, overall mean BG and per-patient mean BG 
is reported for each arm, and compared here to simulation 
results.  
Simulation results compare per-protocol NICE-SUGAR 
outcomes, where the protocol is followed perfectly, with 
STAR outcomes using 1-3 hourly interventions averaging ~12 
measurements per day. Notably, per protocol, the intensive 
arm of NICE-SUGAR demands at least 24 measurements per 
day, which is well above what was reported (Finfer et al., 
2012). Hence, it is clear that there was clinical non-compliance 
to the protocol as presented. As a result, a further analysis was 
run with the same NICE-SUGAR protocol but averaging 
measurements every 3 hours once in band (4.5-10 mmol/L), as 
an approximation of a safe approach to simulating the 
reduction in measurements seen between clinical data and 
protocol specified measurement rates for the intensive arm. A 
modified NICE-SUGAR (NS-3H) protocol to match average 
reported clinical measurements (~9.4 measures/day) (Finfer et 
al., 2012) is thus simulated. NS-3H uses 3 hourly 
measurements if the measured BG is within the band, but is 
maintained to 1 hour if an important decrease (≥ 1.9 mmol/L 
or ≥ 3.9 mmol/L if current BG is between 4.5-6.0 mmol/L or 
6.1-8.0 mmol/L respectively) is observed. NS-3H and STAR 
difference significance is evaluated using the Fisher exact test 
on exact numbers when percentage is reported, the Wilcoxon 
rank sum test when comparing distributions, or the Welch test 
when mean (SD) is given. 
3. RESULTS 
Simulation results for both protocols and reported values for 
NICE-SUGAR are summarised in Table 1. 
In simulation, STAR provides better performance than NS-IIT 
simulated directly as per protocol, with higher percentage BG 
in the 4.4-8.0 mmol/L range (90.7% vs. 79.9%), and tighter 
median [IQR] per-patient mean BG (6.2 [5.9, 6.6] vs. 6.2 [5.7, 
7.2] mmol/L). STAR also provides better safety from 
hypoglycaemia (5 (1%) vs. 10 (2.5%) patients). The 5th-90th 
percentile range of per-patient mean BG for NICE-SUGAR 
(5.3-9.7mmol/L) indicates ~5% of patients have a mean BG 
above 9.7 mmol/L, matching clinically reported performance, 
whereas STAR’s 5th-90th percentile range is 5.4-8.1 mmol/L. 
Nutrition is similar across the protocols, with a median glucose 
rate of 6.2 and 6.1 g/hr for NS-IIT and STAR respectively. 
Additionally, STAR averages ~12 measurements per day 
where NS-IIT averages ~25. In summary, STAR resulted in 
tighter control to an intermediate level with less variability, 
and did so for a greater number and close to all patients. 
NS-3H protocol results in a mean 10.5 measurement per day, 
matching better the reported value of 9.4. In contrast, per 
protocol, the NICE-SUGAR study would require ~25 
measurements per day, which is 1/hour and not clinically 
feasible (Aragon, 2006, Holzinger et al., 2008, Chase et al., 
2008a). Hence, the simulations captured the workload better 
with the NS-3H case.  
Results show a percentage BG in 4.4-8.0 mmol/L of 80%, a 
median [IQR] per-patient mean BG of 6.4 [5.9 7.4] mmol/L, 
and a mean (SD) BG of 6.4 (1.7) mmol/L. A total of 24 patients 
(6%) experienced severe hypoglycaemia under NS-3H. These 
results match clinically reported values, of mean (SD) BG of 
6.4 (1) mmol/L, and 7% of patients experiencing 
hypoglycaemic event. Hence, the safety and overall per patient 
performance were similar to that reported clinically. 
In terms of insulin administrated, results present disparities 
between the protocols. Reported clinically, NICE-SUGAR 
mean insulin dose (SD) is 50.2 (38.1) U/day. Simulations show 
70.4 (53.5) U/day for STAR and 113.6 (77.2) for NICE-
SUGAR. Finally, NS-3H resulted in 98.9 (66.6) U/day. 
  .  
Table 1 - Simulation results summary and recorded NICE-SUGAR 
clinical outcomes. The symbol “/” is used when data is not reported 
in the original study. Significance level (P<0.05) is indicated with * 
for Welch test, † for the Wilcoxon rank sum test, and ‡ for the Fisher 
exact test. 
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In all cases, insulin dose is higher than that reported clinically, 
suggesting that larger insulin doses were not given in the 
original clinical study, despite a protocol not limiting the rate 
of insulin administration, or that the underlying NICE-
SUGAR cohorts were either more insulin sensitive and/or 
received less nutrition than given to these virtual patients. Any 
or all of these factors may play a role, but with such a large 
peak insulin dose, it would not be surprising to find 
compliance to such recommendations to be low (Penning, 
2014). 
4. DISCUSSION 
The NICE-SUGAR international multicentre study showed 
increased risk of hypoglycaemia and mortality for intensive 
insulin therapy over conventional control (Finfer et al., 2009, 
Finfer et al., 2012). However, these results have been much 
debated and the study design and validity of the results 
questioned (Mesotten and Van den Berghe, 2009, Griesdale et 
al., 2009). The results of this study, based on simulation using 
validated virtual patients, show important differences between 
the original protocol and clinically reported values. 
Simulations based on the original NICE-SUGAR protocol 
show poor performance and similar risks of hypoglycaemia 
than reported. Much more insulin was administered in 
simulation than clinically, and the number of average 
measurement per day was consequently higher, reaching the 
expected value of ~24 measurement per day, as per protocol 
design. All these disparities suggest very poor compliance by 
clinical staff to the protocol, and thus potentially low 
confidence in the NICE-SUGAR protocol, which in turn could 
lead to further lack of compliance in dosing insulin (Chase et 
al., 2008a). 
The NS-3H protocol was implemented in order to match 
clinically reported measurements per day, for comparison of 
results. The goal was to estimate the non-compliance in a way 
that delivered similar workload but could be clinically 
realistic. As a result, similar results were achieved compared 
to those clinically reported. However, much more insulin was 
administered, again per protocol design, where, as noted, 
compliance might be lower given the risks. 
This study has several limitations. Firstly, important details 
pertaining to glycaemic control, such as nutrition type and total 
carbohydrate/dextrose intake, are missing from the original 
NICE-SUGAR paper. In addition, the paper focuses on clinical 
outcomes as per study design, reports few details around the 
distribution of BG outcomes for each study arm. While per-
patient mean BG gives some indication of the differences in 
BG between the study arms, it may not reflect underlying 
protocol performance in that it likely tightens BG distributions 
and does not well reflect incidence of extreme BG values. 
Further, it is influenced by the length of patient stay. 
This study makes several assumptions around measurement 
interval and nutrition when simulating the NICE-SUGAR 
protocol. While necessary, these assumptions may not reflect 
actual clinical practice delivered. However, a measurement 
interval of ~3 hours once BG is within the target band is more 
clinically likely given the impact on nursing workload, and 
more closely matches reported BG measures/day. Nutrition 
wise, simulating with a low-carb enteral nutrition is reflects a 
more conservative approach, as increased dextrose intake 
tends to make glycaemic control more difficult and magnifies 
patient variability. These simulations thus reflect a best case 
outcome for the NICE-SUGAR protocol.  
Finally, a limitation of these simulations is that it relies on 
virtual patients drawn from a different ICU cohort than those 
in the NICE-SUGAR study. These patients may thus have a 
different underlying SI than the NICE-SUGAR patients, a 
result which may affect the amount of insulin dosed in 
simulation. However, previous work has shown similar 
variability in SI between different ICU cohorts, which enables 
virtual patients to give consistent BG outcomes in simulation 
(in review). Thus, virtual patients are generalizable in the sense 
of predicting BG outcomes, and these simulation results are 
likely to reflect NICE-SUGAR protocol dynamics. 
Glycaemic control protocols need to be both safe and effective 
for all patients, and be able to account for patient variability, 
before potential clinical benefits can be assessed (Penning et 
al., 2015, Chase et al., 2008a, Krinsley and Preiser, 2015, 
Signal et al., 2012). Indeed, meta-analysis studies have 
recently shown that studies where glycaemic protocols 
achieved the targeted range reported reduced mortality, while 
others showed no beneficial outcome or increased mortality 
(Mesotten and Van den Berghe, 2009, Griesdale et al., 2009). 
These simulations suggest that there was poor compliance to 
the NS-IIT protocol, and subsequent low time (45%) in the 
targeted BG range (4.5 – 6.0 mmol/L), and increased 
hypoglycaemia contributed to poor outcomes in the intensive 
group. 
5. CONCLUSION 
This study compared NICE-SUGAR and STAR protocols on 
validated virtual patients. NICE-SUGAR simulation outcomes 
were also compared to clinically reported data. Per-protocol, 
STAR showed safer and tighter control than NICE-SUGAR. 
Comparing with published values, results were completely 
different, suggesting a real lack in compliance. NICE-SUGAR 
protocol was slightly modified to match the number of 
measurements per day published. The results were 
comparable.  
NICE-SUGAR was unable to achieve safe and effective 
control for all patients, and thus potential clinical benefits 
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